Literature DB >> 10374963

African swine fever virus: a B cell-mitogenic virus in vivo and in vitro.

H Takamatsu, M S Denyer, C Oura, A Childerstone, J K Andersen, L Pullen, R M Parkhouse.   

Abstract

The two major characteristics of pathogenesis in African swine fever virus (ASFV) infections of domestic pigs are massive B-cell apoptosis and haemorrhage. The effects of ASFV on porcine B cells have therefore been systematically examined in vivo, by using virus-infected pigs and SCID-Beige mice reconstituted with porcine bone marrow, and in vitro, by using porcine B-cell lines and B cells from normal and ASFV-infected pigs. Secretion of porcine Ig was stimulated by ASFV both in vivo and in bone marrow cultures in vitro, with the virulent Malawi isolate of ASFV being the most effective. Stimulation of Ig secretion in vitro depended on the presence of ASFV-infected macrophages and did not occur with supernatants from ASFV-infected macrophages. Although the virus alone did not stimulate proliferation of purified B cells in vitro, it was co-stimulatory with CD154 (CD40 ligand). The B cells recovered from ASFV-infected porcine lymphoid tissue were of activated surface marker phenotypes and, interestingly, expressed diminished levels of the B-cell co-stimulatory surface molecule CD21. In addition, they were highly sensitive to IL-4 and CD154. These results may be integrated into a model of pathogenesis in which those B cells activated indirectly as a result of virulent ASFV infection of macrophages are not rescued from apoptosis through interaction with CD154, due to the drastic depletion of T cells that occurs early in infection. The consequently diminished specific anti-ASFV antibody response would favour survival of the virus, with the non-specific hypergammaglobulinaemia being perhaps another example of pathogen-mediated immune deviation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10374963     DOI: 10.1099/0022-1317-80-6-1453

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  7 in total

1.  Kinetic mechanism of the ssDNA recognition by the polymerase X from African Swine Fever Virus. Dynamics and energetics of intermediate formations.

Authors:  Maria J Jezewska; Michal R Szymanski; Wlodzimierz Bujalowski
Journal:  Biophys Chem       Date:  2011-04-28       Impact factor: 2.352

Review 2.  An Overview of Animal Models for Arthropod-Borne Viruses.

Authors:  Erin S Reynolds; Charles E Hart; Meghan E Hermance; Douglas L Brining; Saravanan Thangamani
Journal:  Comp Med       Date:  2017-06-01       Impact factor: 0.982

3.  CD1d mediates T-cell-dependent resistance to secondary infection with encephalomyocarditis virus (EMCV) in vitro and immune response to EMCV infection in vivo.

Authors:  Petr O Ilyinskii; Ruojie Wang; Steven P Balk; Mark A Exley
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

4.  HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals.

Authors:  S Moir; A Malaspina; K M Ogwaro; E T Donoghue; C W Hallahan; L A Ehler; S Liu; J Adelsberger; R Lapointe; P Hwu; M Baseler; J M Orenstein; T W Chun; J A Mican; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

5.  African swine fever virus infection of porcine aortic endothelial cells leads to inhibition of inflammatory responses, activation of the thrombotic state, and apoptosis.

Authors:  I Vallée; S W Tait; P P Powell
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

6.  Pathology of porcine peripheral white blood cells during infection with African swine fever virus.

Authors:  Zaven Karalyan; Hovakim Zakaryan; Hranush Arzumanyan; Khachik Sargsyan; Henrik Voskanyan; Lina Hakobyan; Liana Abroyan; Aida Avetisyan; Elena Karalova
Journal:  BMC Vet Res       Date:  2012-02-28       Impact factor: 2.741

7.  Thoughts on African Swine Fever Vaccines.

Authors:  Daniel L Rock
Journal:  Viruses       Date:  2021-05-20       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.